Pe­ter Dia­man­dis' right hand man Sergey Young wants to re­verse ag­ing via his $100M Longevi­ty Vi­sion Fund

In­spired by British bil­lion­aire Jim Mel­lon, chair­man of an­ti-ag­ing up­start biotech ven­ture Ju­ve­nes­cence, Sergey Young un­veiled a $100 mil­lion fund on Mon­day to cat­alyze the de­vel­op­ment of a com­pre­hen­sive so­lu­tion to coun­ter­act the dam­ag­ing con­se­quences of ag­ing.

“I’ve nev­er looked like my age…and with my name, I think it was pre­de­ter­mined that I was go­ing to work in the space (of ag­ing),” Young told End­points News. The 47-year-old con­sid­ers him­self a prod­uct of Pe­ter Dia­man­dis — the man be­hind the non-prof­it XPRIZE and ven­ture cap­i­tal fund BOLD Cap­i­tal Part­ners — and is in charge of all things longevi­ty at both or­ga­ni­za­tions.

Jim Mel­lon

Like Mel­lon, who penned Ju­ve­nes­cence: In­vest­ing in the Age of Longevi­ty pri­or to the launch of the com­pa­ny Ju­ve­nes­cence, Young is in the em­bry­on­ic stage of writ­ing his own book de­signed to de­code the sci­ence of ag­ing for the mass­es. Mean­while, his $100 mil­lion Longevi­ty Vi­sion Fund will back or­ga­ni­za­tions who are work­ing on tech­nol­o­gy to re­verse the ag­ing process and pro­long healthy hu­man life.

“Adding 20 to 30 healthy years on a per­son’s life is like­ly to be the largest mar­ket op­por­tu­ni­ty on earth. The con­ver­gence of Genome Se­quenc­ing, AI & Cel­lu­lar Med­i­cine will en­able break­throughs that will make 100 years old the new 60. I’m proud through our BOLD Cap­i­tal part­ner­ship to sup­port Sergey Young and the Longevi­ty Vi­sion Fund,” Pe­ter Dia­man­dis said in a state­ment.

Young did not dis­close the deals his fund is cur­rent­ly ex­plor­ing but laid out the ar­eas he is in­ter­est­ed in pur­su­ing.

Pe­ter Dia­man­dis

“We are cur­rent­ly work­ing on 6 deals…and are look­ing at all the usu­al sus­pects in terms of themes” he said. These ar­eas in­clude ear­ly de­tec­tion of se­ri­ous dis­eases us­ing ul­tra­sound tech­nol­o­gy; ear­ly di­ag­nos­tics for heart, can­cer and neu­rode­gen­er­a­tive dis­eases; stem-cell and mi­cro­bio­me-based ther­a­peu­tics; and big da­ta as well as AI-based ap­pli­ca­tions.

Un­sur­pris­ing­ly, Young is in di­a­logue with Alex Zha­voronkov’s AI shop at In­sil­i­co Med­i­cine. Zha­voronkov has deep con­nec­tions in the R&D space — last year he raised funds at the be­hest of Shang­hai high-fly­er WuXi AppTec, Sin­ga­pore’s Temasek, Pe­ter Dia­man­dis and Ju­ve­nes­cence.

“We do plan to par­tic­i­pate in the next round of fund­ing to be­come a share­hold­er of In­sil­i­co,” Young said. It is a mu­tu­al ap­pre­ci­a­tion so­ci­ety here at the Longevi­ty Lead­ers Con­gress in Lon­don, where Zha­voronkov is heard in­tro­duc­ing Young as a vi­sion­ary fund man­ag­er to a con­fer­ence at­tendee. Young, Zha­voronkov, Mel­lon and a host of oth­ers high-pro­file C-suite reg­u­lars in­volved in ag­ing R&D have flocked to a ho­tel near the renowned St Paul’s Cathe­dral to dis­cuss re­cent de­vel­op­ments in an­ti-ag­ing. In the first keynote pan­el of the day, vice pres­i­dent of Ju­ve­nes­cence-backed AgeX Aubrey de Grey am­bi­tious­ly claims that that longevi­ty space will even­tu­al­ly “dwarf the dot­com boom.”

Alex Zha­voronkov

But more fund­ing is nec­es­sary, Zha­voronkov told End­points News at the con­fer­ence. Oth­er than Google’s an­ti-ag­ing biotech Cal­i­co that has seen a large in­flux of funds, the field of an­ti-ag­ing is ripe for in­vest­ment, he said.

For long-time in­vestor and ven­ture cap­i­tal­ist Young, who has in­sight in­to the ag­ing R&D ef­fort with­in the US and to a less­er ex­tent in the UK, Chi­na and In­dia’s siz­able pop­u­la­tions pose com­pelling prospects for deals for his fund.

“In the next decade, ad­vance­ments will al­low us to be a lot more pre­dic­tive and pre­ven­ta­tive in the most dam­ag­ing dis­eases,” he said. “I’m think­ing AI-en­abled med­i­cine will em­pow­er doc­tors…tech­no­log­i­cal ad­vances to im­prove sleep­ing and med­i­ta­tion will emerge — and these are an es­sen­tial part of a healthy, long life, along with a plant-based di­et.”


Im­age: Sergey Young. LONGEVI­TY VI­SION FUND

In a sec­ond big set­back for Covid-19 an­ti­body treat­ment hopes, Re­gen­eron halts en­roll­ment for more se­vere pa­tients

Regeneron has just delivered more bad news for the hope that neutralizing antibodies could be used to treat patients with more severe forms of Covid-19.

The New York biotech said today that an independent monitoring committee recommended halting enrollment of patients who need high-flow oxygen or mechanical ventilation in one of the trials on their antibody cocktail, after finding “a potential safety signal” and “an unfavorable risk/benefit profile.” The news comes a week after the NIH scrapped a trial of Eli Lilly’s Covid-19 antibody after finding it was having little effect on an initial cohort of hospitalized patients.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,900+ biopharma pros reading Endpoints daily — and it's free.

George Golumbeski (L) and Faheem Hasnain

George Golumbes­ki and Fa­heem Has­nain team up with Ver­tex Ven­tures HC in man­ag­ing $320M of biotech cash

Two longtime biotech veterans are joining a multibillion dollar VC firm in order to help steer its latest fund.

George Golumbeski and Faheem Hasnain have signed on to Vertex Ventures HC as executive advisors, the company announced Thursday, and will assist with their depth of experience in managing $320 million of capital. Both have had previous working relationships with managing partners Carolyn Ng and Lori Hu, which evolved “organically” to get to this point, Ng said.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,900+ biopharma pros reading Endpoints daily — and it's free.

Patrick Soon-Shiong at the JP Morgan Healthcare Conference, Jan. 13, 2020 (David Paul Morris/Bloomberg via Getty Images)

Af­ter falling be­hind the lead­ers, dissed by some ex­perts, biotech show­man Patrick Soon-Sh­iong fi­nal­ly gets his Covid-19 vac­cine ready for a tri­al. But can it live up to the hype?

In January, when dozens of scientists rushed to start making a vaccine for the then-novel coronavirus, they were joined by an unlikely compatriot: Patrick Soon-Shiong, the billionaire doctor most famous for making big, controversial promises on cancer research.

Soon-Shiong had spent the last 4 years on his “Cancer Moonshot,” but part of his project meant buying a small Seattle biotech that specialized in making common-cold vectors, called adenoviruses, to train the immune system. The billionaire had been using those vectors for oncology, but the company had also developed vaccine candidates for H1N1, Lassa fever and other viruses. When the outbreak began, he pivoted.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,900+ biopharma pros reading Endpoints daily — and it's free.

Daphne Koller, Getty

Bris­tol My­er­s' Richard Har­g­reaves pays $70M to launch a neu­rode­gen­er­a­tion al­liance with a star play­er in the ma­chine learn­ing world

Bristol Myers Squibb is turning to one of the star upstarts in the machine learning world to go back to the drawing board and come up with the disease models needed to find drugs that can work against two of the toughest targets in the neuro world.

Daphne Koller’s well-funded insitro is getting $70 million in cash and near-term milestones to use their machine learning platform to create induced pluripotent stem cell-derived disease models for ALS and frontotemporal dementia.

Bel­licum slash­es 79% of staffers af­ter ear­ly da­ta quash hope around next-gen CAR-T

Bellicum Pharmaceuticals tried to make it work.

Over the past months the Houston-based CAR-T player sold its manufacturing facility to MD Anderson — transferring 35 employees in the process — in favor of an outsourced arrangement and completed a reverse stock split, while dribbling out new data and getting an IND cleared.

But new interim data from a Phase I/II trial provided the last straw. Bellicum disclosed late Thursday that it will be laying off 79% of its staff, shaving the workforce from 68 to just 14 by the end of 2020.

As­traZeneca sells off heart fail­ure and hy­per­ten­sion drugs to Chep­lapharm for $400M

Out with the old and in with the new: AstraZeneca is selling off two heart failure and hypertension drugs to Germany-based Cheplapharm, bagging $400 million and making way for development in other areas.

Cheplapharm paid $200 million for the European rights to Atacand (candesartan cilexetil) and Atacand Plus (candesartan cilexetil and hydrochlorothiazide) back in 2018. They’re now doubling that amount for commercial control in more than 70 countries.

News brief­ing: Ax­o­vant faces months of de­lay on lead Parkin­son's gene ther­a­py; Chi­nese CAR-T biotech nabs $100M

One of Axovant’s top gene therapy prospects for its second act is hitting a roadblock that could push its clinical timelines back by almost a year.

In an update, the biotech said it was informed about delays in CMC data and third-part fill-finish issues around mid-October by its manufacturing partner, Oxford Biomedica. Axovant has been developing a suspension-based process for the Parkinson’s drug; with that taking longer than expected, it now believes “it is unlikely that its planned randomized, sham-controlled trial of AXO-Lenti-PD will enroll patients by the end of calendar year 2021.”

Ugur Sahin, BioNTech CEO (Andreas Arnold/picture-alliance/dpa/AP Images)

Covid-19 roundup: Flush with $486M con­tract, As­traZeneca signs Lon­za up to man­u­fac­ture an­ti­bod­ies; BioN­Tech's Ugur Sahin ex­pects vac­cine da­ta 'in a fort­night'

Days after scoring a $486 million BARDA contract to develop and manufacture its long-acting antibody combo for Covid-19, AstraZeneca has tapped Lonza to produce the drug substance at its mid-scale facility in Portsmouth, NH.

The drug, dubbed AZD7442, puts together two antibodies, first discovered by scientists at Vanderbilt University Medical Center, derived from convalescent patients who recovered from a SARS-CoV-2 infection. AstraZeneca licensed them in June and has since further engineered them with half-life extension and reduced Fc receptor binding.

CEO Kenji Yasukawa (Astellas)

In ear­ly blow to Ken­ji Ya­sukawa's R&D re­vamp, Astel­las drops out of the TIG­IT race, cit­ing PhI fail­ure

Just after AstraZeneca jumped into the TIGIT race, Astellas quietly disclosed that it was leaving, dropping out of a hunt for an immunotherapy approach that has shown tantalizing promise but remains largely unproven.

Astellas revealed in their second quarter earnings today that they’ve ended development of the anti-TIGIT antibody they acquired in their up to $400 million buyout of Potenza in 2018. The Japanese pharma had been testing it in combination with Keytruda in a 300-person Phase I study on patients with advanced solid tumors. A smaller study testing the antibody alone was completed, 2 years ahead of schedule, in July.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,900+ biopharma pros reading Endpoints daily — and it's free.